All Special Issues
Special Issue Guidelines
Metabolic Control of Diabetes
Dr. Ahmed Bakillah,
SUNY Downstate Medical Center
Dr. Ahmed Bakillah is a visiting Research Assistant Professor at Suny Downstate Medical Center, Brooklyn, NY-USA. He also currently serves as the Managing Editor of Nutrition and Metabolism Journal, BioMed Central Ltd, London-United Kingdom. He received his Ph.D. in Biochemistry from Rene Descartes Paris University in 1994. From 2000 to 2008 he worked at Pharmaceutical Companies (Novo Nordisk & GSK) as Principal Investigator. His primary research interests focus on cardiovascular metabolic diseases and lipid and lipoprotein metabolism. He has published numerous highly cited journal publications, conference articles and book chapters in the CVD and lipids field, and has received several awards and grants from various funding agencies.
About the Special Issue
Tackling diabetes is one of the major health challenges of our time. Approximately, 347 million people worldwide have diabetes; among them almost half a million children are under the age of 14. Approximately 50% of diabetics show diabetes vascular complications by the time they are diagnosed. Ongoing research is now focusing on newer alternative therapeutic agents that have potential to affect primary mechanisms contributing to the pathogenesis of vascular diabetic complications. The purpose of this special issue is to publish high-quality research papers as well as review articles addressing advances and current therapies allowing better glycemic control while minimizing the risk of metabolic and cardiovascular diseases that are associated with the progression and development of diabetes.
Potential topics include, but are not limited to:
- Metabolic dysfunction and glycemic control in diabetes.
- Update on current therapies in the pharmacological management of diabetes.
- New options for insulin analogues delivery and the problematic of hypoglycemia and weight gain.
- Gut microbiota, immunity and inflammation in diabetes.
- Epigenetics and cardiovascular disease in diabetes.
- Oxidative stress genes, antioxidants and coronary artery disease in diabetes.
- Diabetic dyslipidemia and lipid and lipoprotein metabolism: Impact of lipases
- Molecular mechanisms of metabolic dysfunction and physiopathology of vascular complications of diabetes.
- Managing diabetes in patients with chronic kidney disease.
- New insights into diabetes cell therapy.
Inflammatory Basis of Cardiovascular Disease, Cancer and Diabetes
Dr. David P Hajjar,
Weill Cornell Medicine, Cornell University
Dr. David P. Hajjar received his Ph.D. in 1978 from the University of New Hampshire. He is currently University Distinguished Professor and Professor of Biochemistry and Pathology at Weill Cornell Medicine at Cornell University in New York City where he has been on the faculty since 1981. He has published over 170 papers in cardiovascular research. He is also Dean Emeritus of the Weill Cornell Graduate School of Medical Sciences in New York. He is a member of the American Academy of Arts and Sciences, and Associate Editor of the Journal of Enzymology and Metabolism. He is the recipient of many scientific awards form the Andrew Mellon Foundation, the American Heart Association and the FASEB society.
About the Special Issue
This special issue was created since cardiovascular diseases (CVD), diabetes, and cancer share commonalities involving metabolic disturbances that reflect dysregulated energy homeostasis and metabolic control. To date, how these processes relate physiologically remains undefined. According to the Centers for Disease Control and Prevention, these diseases can affect most Americans, and a steady increase in disease burden is predicted for the remainder of the 21st century. Changes in metabolic pathways, many of which are influenced by inflammation, are associated with CVD, type 2 diabetes, and cancer. Although a number of key regulatory molecules including specific receptors have been identified, their utility as therapeutic targets is limited by the multiplicity of intersecting pathways in which they participate. Hence, we invite investigators to contribute research articles and review papers to the Journal of Enzymology and Metabolism that address these issues as well as papers which discuss the current advances made in understanding the role of potential biological response modifiers that could be proven to be central to designing effective treatments for these diseases.
In this issue, papers will be accepted covering the following general topics:
- The role of inflammatory pathways and their antagonists in CVD, diabetes, and cancer.
- The role of the receptors for advanced glycation end-products (RAGE) and oxidized lipoproteins in the pathogenesis of metabolic disorders, including obesity and diabetes
- The impact of inflammation-based clinical treatments for CVD, diabetes and cancer
- The role of enzymology in the identification of common metabolic links of these diseases